Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 - - Tourmaline ...

Detailed price information for Tourmaline Bio Inc (TRML-Q) from The Globe and Mail including charting and trades.

The Hummingbird Diagnostics Product Pipeline Analysis highlights the company's miRNA-based liquid biopsy innovations for early detection of cancer, ...

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 ...

LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International AB ("BioInvent") , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announcedthat the company will present three ...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced the presentation of ...

“The excellent survival responses reported in patients with different tumor types in the Phase 2 study is very exciting, and we look forward to seeing these promising data replicate in the pivotal ...